A Hong Kong R&D entity connected to in-house manufacturing
Founded in Hong Kong in 2026 for global overseas business development, Hytanbio Tech is a biological research and development entity focused on translating delivery-system concepts into export-ready commercial projects. Its large-scale commercial manufacturing facility was established in 2014 in Shaoxing, Mainland China and operates as the in-house production base. This structure gives overseas brand teams a single commercial interface while retaining direct access to formulation, pilot work, production planning and quality documentation. The website focuses on pet oral dissolving film programs, one application within a broader platform that also works with peptide raw materials, lyophilized peptide powder, dissolvable microneedle patches and oral-film delivery systems.
Research infrastructure supports feasibility-led decisions
The R&D center covers more than 4,000 square meters and includes multiple peptide production lines, large-scale peptide synthesizers, advanced analytical and preparative HPLC systems and clean laboratory environments. For oral-film programs, the practical value is the ability to connect material knowledge, prototype preparation, analytical review and scale-up questions early. Hytanbio states that its quality management system complies with ISO 9001:2015; the scope and current certificate can be provided for buyer verification during due diligence. Other site, product or food-safety certifications are not implied by that statement and are disclosed only when the applicable evidence has been confirmed.
End-to-end support from brief to export handover
Projects can include formula feasibility assessment, prototype sampling, specification confirmation, packaging coordination, batch-specific quality documentation and export handover. Scientist-led teams work across research, pilot trials and commercial production so technical decisions do not disappear when a project leaves the laboratory. The company serves brand owners, product developers, distributors, laboratories, beauty and wellness businesses and cross-border operators. Pet programs are handled as species- and market-specific work: the buyer’s target claims, ingredients, pack and destination are reviewed before a commercial recommendation is made.
What buyers can expect from the working relationship
Hytanbio prioritizes written specifications, defined approval points and traceable change control. A realistic project may involve iterations because taste, active load, film strength, moisture behavior and label rules can conflict. The team documents open decisions, separates prototype observations from verified commercial data and identifies where the brand owner or importer needs independent regulatory advice. This approach is less dramatic than publishing universal claims, but it gives serious B2B buyers a clearer basis for technical review, cost comparison and launch planning.